- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07621094
Intraosseous Antibiotics for Osseointegration (IOAOI)
The purpose of this research study is to learn about the characteristics of infection in osseointegration patients. This research study will also study how safe and effective it is to use antibiotics inside the bone.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The goal of this multi-center prospective trial is to assess the characteristics of infection among patients with osseointegrated prosthesis and the safety and effectiveness of intraosseous antibiotic delivery.
Participants will enroll in an observational arm. Participants who require surgery for infection may enroll in an interventional arm assessing the safety and feasibility of intraosseous antibiotic administration as a potential treatment for infection.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Christine Churchill, MA
- Número de telefone: 704-355-6947
- E-mail: Christine.Churchill@advocatehealth.org
Locais de estudo
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Anschutz Medical Campus
-
Contato:
- Mohamed Awad, MD
- Número de telefone: 706-832-9969
- E-mail: mohamed.awad@cuanschutz.edu
-
Investigador principal:
- Danielle Melton, MD
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Hospital for Special Surgery
-
Contato:
- Lediona Ardolli
- Número de telefone: 646-714-6362
- E-mail: ardollil@hss.edu
-
Investigador principal:
- S. Robert Rozbruch, MD
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Atrium Health Carolinas Medical Center
-
Investigador principal:
- Joseph R Hsu, MD
-
Contato:
- Rachel B Seymour, PhD
- Número de telefone: 704-441-5365
- E-mail: Rachel.Seymour@advocatehealth.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania Perelman School of Medicine
-
Investigador principal:
- Benjamin Potter, MD
-
Contato:
- Annamarie Horan, PhD
- Número de telefone: 215-847-0132
- E-mail: horana@pennmedicine.upenn.edu
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78229
- UT Health San Antonio
-
Contato:
- Nick Lucio, BA
- Número de telefone: 210-567-5142
- E-mail: luciond@uthscsa.edu
-
Investigador principal:
- Joseph Alderete, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Treated with osseointegration for transfemoral, transhumeral, or transtibial amputation and presenting with concern for surgical site infection
- >18 years of age
Exclusion Criteria:
- Unable to follow up at site for 1 year
- Patients that speak neither English nor Spanish
- <18 years of age
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Observational
Patients that do not require surgery for infection |
|
|
Experimental: Intraosseous Antibiotics for Osseointegration
Patients that require surgery for infection |
After debridement, patients will receive intraosseous (IO) vancomycin 500mg in 150ml of normal saline during surgery. The solution will be prepared by the hospital pharmacy and administered via an IO cannula. The cannula will be placed proximal to the intramedullary fixture. In cases where a tourniquet can be utilized proximal to the IO cannula, the antibiotic is delivered as a bolus. Tourniquet must be up for 1 hour after installation of the IO cases where the residual limb is too short to allow tourniquet (pneumatic or elastic) proximal to the IO cannula, the intraosseous antibiotic must be infused at a rate not to exceed 10mg/min or less. This can be accomplished by connecting intravenous tubing to the antibiotic mixture and the IO cannula. In cases without a tourniquet, IO infusion should begin during the irrigation phase and continue through the complete closure of the wound, since it requires a significant amount of time 50-60 min. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Patients Who Develop Wound Dehiscence
Prazo: Week 2
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Week 2
|
|
Number of Patients Who Develop Wound Dehiscence
Prazo: Week 6
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Week 6
|
|
Number of Patients Who Develop Wound Dehiscence
Prazo: Month 3
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 3
|
|
Number of Patients Who Develop Wound Dehiscence
Prazo: Month 6
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 6
|
|
Number of Patients Who Develop Wound Dehiscence
Prazo: Month 12
|
Wound Dehiscence is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is Yes/No. |
Month 12
|
|
Number of Patients Who Develop Superficial Infection
Prazo: Week 2
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Week 2
|
|
Number of Patients Who Develop Superficial Infection
Prazo: Week 6
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Week 6
|
|
Number of Patients Who Develop Superficial Infection
Prazo: Month 3
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 3
|
|
Number of Patients Who Develop Superficial Infection
Prazo: Month 6
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 6
|
|
Number of Patients Who Develop Superficial Infection
Prazo: Month 12
|
Superficial Infection is a complication that is assessed by the surgeon and clinical team and is documented in the patient's chart. It is yes/no. |
Month 12
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Prazo: Week 2
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Week 2
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Prazo: Week 6
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Week 6
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Prazo: Month 3
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 3
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Prazo: Month 6
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 6
|
|
Number of Patients Who Develop Deep Surgical Site Infection
Prazo: Month 12
|
Number of participants in each group who develop surgical site infection as defined by the criteria establish by the Centers for Disease Control and Prevention (CDC). The CDC criteria define deep as occurring within 30 or 90 days after the procedure. However, we will continue to follow patients for 12 months and document any infections and other complications during this period. |
Month 12
|
|
Number of Patients With Treatment Failure
Prazo: Week 2
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Week 2
|
|
Number of Patients With Treatment Failure
Prazo: Week 6
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Week 6
|
|
Number of Patients With Treatment Failure
Prazo: Month 3
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 3
|
|
Number of Patients With Treatment Failure
Prazo: Month 6
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 6
|
|
Number of Patients With Treatment Failure
Prazo: Month 12
|
Treatment failure is defined as explant of the OI implant for any reason. Treatment failure will also be defined as additional surgical complications, wound complications, need for chronic antibiotic suppression, readmission, and reoperation. |
Month 12
|
|
Rate of Adverse Events
Prazo: Week 2
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Week 2
|
|
Rate of Adverse Events
Prazo: Week 6
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Week 6
|
|
Rate of Adverse Events
Prazo: Month 3
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 3
|
|
Rate of Adverse Events
Prazo: Month 6
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 6
|
|
Rate of Adverse Events
Prazo: Month 12
|
The proportion of participants experiencing ≥1 adverse event during the study period will be assessed to evaluate safety. Adverse events include any unfavorable or unintended medical occurrence, regardless of relatedness, including surgical, infectious, wound-related, or systemic events. Events will be collected prospectively and categorized by severity and relatedness. |
Month 12
|
|
Rate of antibiotic-complications
Prazo: Week 2
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Week 2
|
|
Rate of antibiotic-complications
Prazo: Week 6
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Week 6
|
|
Rate of antibiotic-complications
Prazo: Month 3
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 3
|
|
Rate of antibiotic-complications
Prazo: Month 6
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 6
|
|
Rate of antibiotic-complications
Prazo: Month 12
|
The proportion of participants experiencing ≥1 antibiotic-related complication during treatment will be assessed. Complications include clinically significant events attributable to antibiotic exposure (e.g., allergic reactions, gastrointestinal intolerance, hepatotoxicity, nephrotoxicity, hematologic abnormalities, or local administration-related reactions). Events will be identified through clinical assessment, laboratory data, and medical record review. |
Month 12
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS -29)
Prazo: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The PROMIS-29 is a free to use, publicly available generic health related quality of life measure that includes seven domains: depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities. A 5-point Likert scale is used for each question and norm-based total scores (range 0-100) have been calculated so that 50 represents the mean and one standard deviation is 10 points. Higher scores represent better function. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Veterans RAND 12 (VR-12) Health Survey - Physical Component Score
Prazo: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The VR-12 is a measure of global health that corresponds to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health. Together, these items are summarized into a Physical Component Score. The mean score is 50 with a standard deviation of 10. Higher scores indicate better average health (higher than 50 means better than average health, below 50 means below average health). |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Veterans Rand 12 (VR12) Health Survey - Mental Component Score
Prazo: 2 weeks, 6-weeks, 3-months, 6-months, 12-months
|
The VR-12 is a measure of global health that corresponds to seven domains: general health, physical functioning, role limitations, pain, fatigue, social functioning, and mental health. Together, these items are summarized into a Mental Component Score. The mean score is 50 with a standard deviation of 10. Higher scores indicate better average health (higher than 50 means better than average health, below 50 means below average health). |
2 weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Pain - Numeric Rating Scale
Prazo: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
A scale from 0-10, where 0 is no pain and 10 is the worst pain. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
|
Pain - Brief Pain Inventory (BPI)
Prazo: 2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
The BPI is a commonly used, validated 15-item measure of pain intensity and interference with daily life. There is a pain severity score and a pain interference score. Both are 0-10, with 0 being no pain and 10 being worst pain imaginable (for pain severity) and 0 being does not interfere and 10 being completely interfered (for pain interference). Lower scores are better. |
2-weeks, 6-weeks, 3-months, 6-months, 12-months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Joseph R Hsu, MD, Wake Forest University Health Sciences
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRB00147620
- 40010222 (Outro identificador: Department of Defense)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .